Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held virtually May 11 – 14, 2021.
Editas Medicine Scientist Heather MacLeod, Ph.D., will speak at the ASGCT Gene Editing Workshop. Her presentation, The Development of CRISPR Based Medicines for the Treatment of Ocular Diseases, will be part of ASGCT’s pre-meeting program Moving Genome Editing to the Clinic: From Technology to Therapeutics. In addition, the Company is presenting preclinical data demonstrating therapeutically relevant levels of editing using a dual AAV CRISPR-Cas9 system as a therapeutic strategy for the treatment of retinitis pigmentosa 4 (RP4) on May 11.
Full details of the Editas Medicine presentations can be accessed on the ASGCT website at https://annualmeeting.asgct.org/abstracts.
Research Collaboration Poster Presentation (Editas Medicine Author):
About Editas Medicine
Contacts: Media Cristi Barnett (617) 401-0113 firstname.lastname@example.org Investors Ron Moldaver (617) 401-9052 email@example.com
MSPs and the IT Skills Gap
Encoding Values Into a New Generation of Technology